Decreased ability of HIV-1 tat protein-treated accessory cells to organize cellular clusters is associated with partial activation of T cells

Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13832-7. doi: 10.1073/pnas.94.25.13832.

Abstract

It has been shown in several animal models that HIV infection of accessory cells (ACs) plays an important role in development of AIDS. Here, we report that ACs treated with HIV-1 Tat protein (Tat-ACs) have a decreased ability to organize cellular aggregates as compared with untreated ACs, resulting in incomplete activation of T cells in responses to anti-CD3 mAb or staphylococcal enterotoxin B stimulation. The T cells failed to up-regulate adhesion molecules CD11a and CD2 on the cell surface and had reduced proliferative responses, as determined by [3H]thymidine incorporation, but they obtained lymphoblast-like morphology and expressed early activation antigens on the cell surface such as Fas and CD69 and interleukin 2 receptor, at comparable levels as those T cells undergoing a maximal proliferation. These results suggest that the Tat-AC-induced defect occurs in the late, but not in the early, phases of T cell activation. Normal expression of cell surface Fas antigen accompanied by defects in late activation thus may result in the susceptibility of these T cells to apoptosis. Our studies suggest that dysfunction, hyperactivation, and susceptibility to apoptosis, as observed with T cells isolated from HIV-infected individuals, may be, at least in part, a consequence of abnormal functions of ACs.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antigen-Presenting Cells / cytology*
  • Antigen-Presenting Cells / drug effects
  • Antigen-Presenting Cells / immunology*
  • Apoptosis
  • Cell Aggregation
  • Cell Division
  • Gene Products, tat / immunology
  • Gene Products, tat / pharmacology
  • Gene Products, tat / physiology*
  • HIV Infections / immunology
  • HIV Infections / pathology
  • HIV Infections / virology
  • HIV-1 / immunology
  • HIV-1 / pathogenicity*
  • HIV-1 / physiology*
  • Humans
  • In Vitro Techniques
  • Lymphocyte Activation
  • T-Lymphocytes / cytology
  • T-Lymphocytes / immunology*
  • tat Gene Products, Human Immunodeficiency Virus

Substances

  • Gene Products, tat
  • tat Gene Products, Human Immunodeficiency Virus